Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
15.73
-1.03 (-6.15%)
At close: Oct 23, 2026, 4:00 PM EDT
15.80
+0.07 (0.45%)
After-hours: Oct 23, 2026, 7:59 PM EDT
Aktis Oncology Revenue
Aktis Oncology had revenue of $3.38M in the quarter ending June 30, 2026, with 133.86% growth. This brings the company's total for the last twelve months to $10.06M, up 576.53% year-over-year. In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth. That makes Aktis Oncology the 37,310th largest company in the world by revenue and 4,888th in the United States.
Revenue (ttm)
$10.06M
Revenue Growth
+576.53%
P/S Ratio
86.97
Revenue / Employee
$127,342
Employees
79
Market Cap
874.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
AKTS News
- 22 days ago - Aktis Oncology initiates second Phase 1b trial for AKY-2519 - TheFly
- 22 days ago - Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 - GlobeNewsWire
- 5 weeks ago - Aktis Oncology Slides: Corporate presentation - Filings
- 5 weeks ago - Aktis Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Oppenheimer bullish on Aktis Oncology, initiates with an Outperform - TheFly
- 6 weeks ago - Aktis Oncology initiated with an Outperform at Oppenheimer - TheFly
- 2 months ago - Wedbush starts Aktis Oncology at Outperform on radiopharma potential - TheFly
- 2 months ago - Aktis Oncology initiated with an Outperform at Wedbush - TheFly